Molecular Diagnostics Market Hits US$ 39.5 Billion in 2022, Expected to Reach US$ 59.4 Billion by 2033 with a 4.2% CAGR, Persistence Market Research
January 16, 2024 10:30 ET
|
Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The Molecular Diagnostics Market is experiencing robust growth due to technological advancements and increasing demand for personalized medicine. Key...
Genomic Cancer Testing is projected to Hit $45.92 Billion, Globally, by 2030 at 16.1% CAGR: Coherent Market Insights
November 07, 2023 02:49 ET
|
CMI
Burlingame, Nov. 07, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global genomic cancer testing market is estimated to be valued at US$ 16.15 billion in 2022 and is expected to...
Florida Cancer Specialists & Research Institute Celebrates Addition of Next-Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care
September 06, 2022 12:26 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation...
Genomic Data Analysis and Interpretation Market Size is projected to reach USD 2.15 Billion by 2030, growing at a CAGR of 10.25%: Straits Research
August 16, 2022 12:10 ET
|
Straits Research
New York, United States, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The term "NGS," for "high throughput sequencing," describes a wide range of cutting-edge sequencing methods. Researchers can study...
Heart Failure POC and LOC Devices Market to Hit $180.1 Million by 2028; Heart Failure POC & LOC Devices Industry CAGR of 16.5% between 2022-2028; Exclusive Insight Report [155 Pages] by Vantage Market Research
March 11, 2022 02:40 ET
|
Vantage Market Research
WASHINGTON, March 11, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Heart Failure POC & LOC Devices Market finds that factors such as, increasing geriatric...
ProPhase Labs Announces $6 Million Stock Repurchase Program
September 08, 2021 08:30 ET
|
ProPhase Labs, Inc.
Garden City, NY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today announced that its Board of Directors has authorized the...
Genomic testing in the U.S. workplace
November 05, 2020 10:00 ET
|
The Jackson Laboratory
Farmington, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- More than 157 million people in the U.S. receive their healthcare insurance through employer health plans. One potential means of enhancing...
Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
October 29, 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
February 24, 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Breast Cancer Index® and new data on its power to predict extended endocrine therapy benefit presented at ASCO 2019
June 03, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, June 03, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3, 2019 that further...